HC Wainwright Has Positive View of Cabaletta Bio Q1 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for Cabaletta Bio in a research report issued on Tuesday, April 1st. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.63) per share for the quarter, up from their previous forecast of ($0.74). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.51) EPS, FY2026 earnings at ($2.46) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.30) EPS.

Cabaletta Bio (NASDAQ:CABA) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.65) EPS for the quarter, meeting analysts’ consensus estimates of ($0.65).

Several other analysts also recently issued reports on CABA. Morgan Stanley cut their target price on shares of Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 1st. Evercore ISI lowered Cabaletta Bio from an “outperform” rating to an “inline” rating and dropped their price target for the company from $15.00 to $6.00 in a research report on Friday, December 20th. UBS Group decreased their price objective on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Guggenheim reiterated a “buy” rating and issued a $23.00 target price on shares of Cabaletta Bio in a report on Tuesday, April 1st. Finally, Wells Fargo & Company lowered their price objective on shares of Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 1st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $21.00.

Cabaletta Bio Price Performance

CABA stock opened at $1.11 on Friday. The firm has a market capitalization of $56.32 million, a P/E ratio of -0.52 and a beta of 2.44. Cabaletta Bio has a 52-week low of $1.08 and a 52-week high of $19.04. The company’s 50 day simple moving average is $1.98 and its 200-day simple moving average is $2.88.

Hedge Funds Weigh In On Cabaletta Bio

Several hedge funds have recently bought and sold shares of CABA. T. Rowe Price Investment Management Inc. lifted its position in shares of Cabaletta Bio by 10.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,074,006 shares of the company’s stock worth $9,248,000 after buying an additional 400,282 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Cabaletta Bio by 19.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,634,473 shares of the company’s stock worth $8,250,000 after purchasing an additional 597,828 shares during the period. Point72 Asset Management L.P. grew its holdings in Cabaletta Bio by 89.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company’s stock valued at $2,874,000 after purchasing an additional 598,607 shares during the last quarter. Geode Capital Management LLC grew its holdings in Cabaletta Bio by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,110,702 shares of the company’s stock valued at $2,522,000 after purchasing an additional 16,058 shares during the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of Cabaletta Bio by 195.8% in the fourth quarter. Two Sigma Advisers LP now owns 831,900 shares of the company’s stock valued at $1,888,000 after purchasing an additional 550,700 shares during the period.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.